Octreotide reduces enteral protein losses in Ménétrier's disease.
A 47-yr-old man with Ménétrier's disease presented with profound enteral protein losses documented by 51Cr-albumin stool studies. There was no response to anticholinergics, H2-receptor antagonists, or proton pump inhibition. Subcutaneous octreotide acetate, 100 micrograms bid, resulted in clinical improvement with rapid resolution of enteral protein losses. Octreotide was continued for 12 months. During an additional 5-month follow-up period without therapy, the patient remained improved clinically with low to normal serum proteins, despite the persistence of gastric rugal hypertrophy. The evidence that octreotide resolved enteral protein losses and eliminated the need for urgent gastrectomy in our patient warrants a trial of this drug for other patients with Ménétrier's disease.
Yeaton
P
P
Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville.
Frierson
H F
HF
D000418:Albumins / Q000032:analysis; D002860:Chromium Radioisotopes; D004815:Epidermal Growth Factor / Q000032:analysis; D005243:Feces / Q000737:chemistry; D005744:Gastric Acid / Q000378:metabolism; D005755:Gastrins / Q000097:blood; D005758:Gastritis, Hypertrophic / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage*; D011504:Protein-Losing Enteropathies / Q000188:drug therapy* / Q000378:metabolism; D012463:Saliva / Q000737:chemistry
D000418:Albumins; D002860:Chromium Radioisotopes; D005755:Gastrins; D004815:Epidermal Growth Factor; D015282:Octreotide